ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network
Aging · 2023
DOI: 10.18632/aging.205327 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging, 2023. Verfasst von Hongyan Qian und 12 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Center Nantong, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong 226361, China. Hauptthemen laut MEDLINE: Breast Neoplasms, X-linked Nuclear Protein, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Center Nantong, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong 226361, China.
- Department of Gynecology Oncology, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong 226361, China.
- Department of Computer Science and Engineering, Tandon School of Engineering, New York University, Brooklyn, NY 11201, USA.
- Department of Pathology, Affiliated Tumor Hospital of Nantong University, Nantong 226361, China.
- Department of Breast Surgery, Affiliated Hospital of Nantong University, Nantong 226001, China.
- School of Medicine, Nantong University, Nantong 226001, China.
Zitieren
APA
Qian, H., Ji, R., Shen, C., Wei, Y., Sheng, C., Ni, Q., Pan, J., Chi, Y., You, H., Miao, Y., Shi, M., Huang, X., & Shen, A. (2023). ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network. Aging. https://doi.org/10.18632/aging.205327
Vancouver
Qian H, Ji R, Shen C, Wei Y, Sheng C, Ni Q, et al. ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network. Aging. 2023. doi:10.18632/aging.205327
BibTeX
@article{Qian2023,
author = {Qian, Hongyan and Ji, Rui and Shen, Cheng and Wei, Yinze and Sheng, Chenyi and Ni, Qichao and Pan, Jing and Chi, Yifan and You, Huan and Miao, Ying and Shi, Minxin and Huang, Xianghua and Shen, Aiguo},
title = {ATRX is a predictive marker for endocrinotherapy and chemotherapy resistance in HER2-/HR+ breast cancer through the regulation of the AR, GLI3 and GATA2 transcriptional network},
journal = {Aging},
year = {2023},
doi = {10.18632/aging.205327}
}
EUVIMED